These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 37286711)

  • 1. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
    Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
    Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DLAT is a promising prognostic marker and therapeutic target for hepatocellular carcinoma: a comprehensive study based on public databases.
    Zhang P; Zhao JH; Yuan LX; Ju LL; Wang HX; Wang F; Chen L; Cai WH
    Sci Rep; 2023 Oct; 13(1):17295. PubMed ID: 37828099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis regulatory genes greatly contribute to clinical assessments of hepatocellular carcinoma.
    Ke C; Dai S; Xu F; Yuan J; Fan S; Chen Y; Yang L; Li Y
    BMC Cancer; 2023 Jan; 23(1):25. PubMed ID: 36611155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
    Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
    Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification.
    Chen Z; Du D; Li J; Zhang W; Shao J
    Transl Cancer Res; 2024 Mar; 13(3):1268-1289. PubMed ID: 38617510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
    Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
    Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
    Li Y; Zeng X
    Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
    [No Abstract]   [Full Text] [Related]  

  • 12. MELK promotes HCC carcinogenesis through modulating cuproptosis-related gene DLAT-mediated mitochondrial function.
    Li Z; Zhou H; Zhai X; Gao L; Yang M; An B; Xia T; Du G; Li X; Wang W; Jin B
    Cell Death Dis; 2023 Nov; 14(11):733. PubMed ID: 37949877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients.
    Bai WD; Liu JY; Li M; Yang X; Wang YL; Wang GJ; Li SC
    World J Oncol; 2022 Oct; 13(5):299-310. PubMed ID: 36406193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
    Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
    Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
    Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Front Genet; 2023; 14():1056000. PubMed ID: 36845390
    [No Abstract]   [Full Text] [Related]  

  • 17. Comprehensive analysis identifies cuproptosis-related gene DLAT as a potential prognostic and immunological biomarker in pancreatic adenocarcinoma.
    Zhang X; Zhou Y; Hu J; Yu X; Xu H; Ba Z; Zhang H; Sun Y; Wang R; Du X; Mou R; Li X; Zhu J; Xie R
    BMC Cancer; 2023 Jun; 23(1):560. PubMed ID: 37330494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
    Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
    Front Immunol; 2022; 13():991604. PubMed ID: 36685508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
    Jiang H; Chen H; Wang Y; Qian Y
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.